Investors & Media

Press Releases

View all press releases »

Ionis to present at TD Cowen Genetic Medicines & RNA Summit

June 17, 2024 at 4:09 PM EDT

CARLSBAD, Calif., June 17, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.

A live webcast of this presentation can be accessed on the Investors & Media section of the Ionis website at A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

To learn more about Ionis, visit and follow us on X (Twitter) and LinkedIn.

Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – – 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley – 760-603-4679

Cision View original content to download multimedia:

SOURCE Ionis Pharmaceuticals, Inc.